15 December 2025 - We are pleased the US FDA has selected the teclistamab MajesTEC-3 supplemental biologics license application to participate in the Commissioner’s National Priority Voucher Pilot Program as it aligns with the program’s priority to deliver more innovative therapies for American people. 

We look forward to working with the US FDA to bring this transformational regimen to patients with multiple myeloma as soon as possible.

Read Johnson & Johnson press release